Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc mouthwash for prevention of oral mucositis after hematopoietic stem cell transplantation
ACTRN12620001188921Phase 2Completed
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of polaprezinc in stomatitis, sponsored by Royal Brisbane and Women's Hospital. Primary endpoint: Incidence of grade 3 or 4 oral mucositis. Started Feb 2021; status: completed.
02
Drugs
polaprezinc
03
Conditions
stomatitis
Beyond the preview
Go deeper on ACTRN12620001188921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001188921.